Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Brain Behav Immun. 2022 Nov 24;108:118–134. doi: 10.1016/j.bbi.2022.11.014

Figure 1: A schematic displaying the various in vivo experiments and analyses performed in the study.

Figure 1:

The sequence comprises the induction of controlled cortical impact injury (CCI), intranasal (IN) administration of hyaluronidase at 60 minutes post-TBI, IN administration of hMSC-EVs at 90 minutes post-TBI, and the timeline of studies in the acute and chronic phases of TBI. The experiments in the acute phase of TBI include analyses of hMSC-EV incorporation into neurons and glia at 6 hours post-EV administration and NLRP3 inflammasome activation in the injured brain at 48 hours after vehicle or hMSC-EV administration. The experiments in the chronic phase of TBI comprise cognitive and mood function tests at 63–83 days post-TBI and brain tissue harvesting at 84 days after vehicle or hMSC-EV administration.